Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kowa Of Japan Buys Control Of ProEthic Of U.S.

This article was originally published in PharmAsia News

Executive Summary

Japan's Kowa now owns 77.9 percent of ProEthic Pharmaceuticals of the United States, the Japanese firm announced. The purchase, valued at as much as $91.3 million, gives Kowa access to a sales network for its Livalo (pitavastatin) drug for treating hyperlipidemia, which the firm expects to launch in the United States in 2010. The U.S. company is to be renamed Kowa Pharmaceuticals America as of Sept. 1. Kowa plans to increase the ProEthic sales force beyond its current 65 people, in part to handle its drug for reducing triglyceride levels. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts